Efficacy and Safety Analysis of Sindilizumab Combined with XELOX Chemotherapy in the Treatment of Advanced Gastric Cancer
Objective To investigate the effect of sindilizumab, oxaliplatin combined with capecitabine (XELOX) in the treatment of advanced gastric cancer.Methods Seventy-six patients with advanced gastric cancer admitted to our hospital from October 2022 to August 2023 were selected as the research objects, and were divided into a control group and an observation group according to random number table method, with 38 cases in each group.The control group was treated with XELOX regimen, and the observation group was treated with sindillizumab on this basis.The levels of tumor markers and toxic side effects were compared between the two groups.Results After 6 cycles of treatment, the control rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05);the serum levels of carcin-oembryonic antigen, carbohydrate antigen 724 and carbohydrate antigen 125 in the two groups were lower than before treatment, and the observation group was lower than the control group, the differences were statistically significant (P<0.05);during treatment, there was no significant difference in toxic and side effects between the two groups (P<0.05).Conclusion Sind-ilizumab combined with XELOX chemotherapy is effective in the treatment of advanced gastric cancer, which can effectively improve tumor metabolism indexes and has certain safety.
NETL
NSTL
万方数据
